Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Grand Pharmaceutical Group's average Total Assets Growth Rate was 14.90% per year.
During the past 3 years, the average Total Assets Growth Rate was 8.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 9.80% per year.
During the past 10 years, the average Total Assets Growth Rate was 15.90% per year.
During the past 13 years, Grand Pharmaceutical Group's highest 3-Year average Total Assets Growth Rate was 119.00%. The lowest was -13.90%. And the median was 25.20%.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Grand Pharmaceutical Group's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Grand Pharmaceutical Group Total Assets Related Terms
Grand Pharmaceutical Group Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Pharmaceutical Group Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Pharmaceutical Group (FRA:MX6A) has a Total Assets of €2,982 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Grand Pharmaceutical Group and its competitors.
Is Grand Pharmaceutical Group's Total Assets too high?
Grand Pharmaceutical Group's current Total Assets is €2,982 Mil. Overall, Grand Pharmaceutical Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's Total Assets compare to ZTS and UTHR?
Grand Pharmaceutical Group's Total Assets of €2,982 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Grand Pharmaceutical Group and its competitors. Grand Pharmaceutical Group's current Total Assets is €2,982 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Grand Pharmaceutical Group (FRA:MX6A) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.62, compared to a current price of €0.55 — trading 12.1% below its estimated fair value. The current Total Assets is €2,982 Mil. Grand Pharmaceutical Group's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Grand Pharmaceutical Group (FRA:MX6A), the current Total Assets is €2,982 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grand Pharmaceutical Group (FRA:MX6A) Overvalued in 2026?
Based on GuruFocus' analysis, Grand Pharmaceutical Group stock appears to be undervalued.
The current stock price of €0.55 is trading 12.1% below its estimated GF Value™ of €0.62.
GuruFocus considers Grand Pharmaceutical Group to be Modestly Undervalued.
Key valuation signals for FRA:MX6A:
Total Assets: €2,982 Mil
GF Value™: €0.62 vs. price of €0.55 (12.1% below fair value)
No single metric tells the full story. See the FRA:MX6A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
86GF Score
Get the complete analysis for FRA:MX6A
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MX6A has been successfully added to your 
